


1 Supplementary figures

2




3

4 **Supplementary figure 1: Initial sample comparison revealed two COVID-19 patients which were subsequently excluded in**
5 **further analyses.** A) Principal Component Analysis (PCA) graph comparing the COVID-19 patients with the influenza patients
6 revealed two COVID-19 outliers (CoV0117 and CoV0271). B) Heatmap comparing the differentially expressed genes found
7 specifically in COVID-19 patients indicates a different expression profile for CoV0117 and CoV0271 compared to the other
8 samples. Assessment of the blood results indicates a high white blood cell count (C) and high lymphocyte count (D) in CoV0117
9 and CoV0271. Subsequent, analysis of the patient metadata revealed that these samples are from two patients with known
10 chronic lymphocytic leukaemia.

11


12



13

14 **Supplementary figure 2: Sequence read depths obtained in the patients with COVID-19 or influenza in reads per million.** A) Comparison of the sequence read depths obtained in the 78 patients with COVID-19 (median sequence depth of 60.4 million reads) and 83 patients with influenza (median sequence depth of 58.9 million reads). B) Sequence read depths in the patients with COVID-19 used for the comparison between survivors (median sequence depth of 62.6 million reads) and non-survivors (median sequence depth of 55.7 million reads). Median sequence depths are illustrated by the black dashed line.


19



20

21 **Supplementary figure 3: PCA analysis between patients with COVID-19 or influenza, and who survived or died of COVID-19.** A) PCA analysis between patients with COVID-19 or influenza showing a substantial overlap between the two different group blood transcriptomes. B) A partial overlap of blood transcriptomes between patients who survived or who died of COVID-19.


25



26

27 **Supplementary figure 4: GO Biological Process Term 'adaptive immune response' gene expression between patients with**
 28 **COVID-19 or influenza.** Unpaired non-parametric Wilcoxon test was used to assess the difference in abundance of 83
 29 immunoglobulin genes associated with the GO biological process term 'adaptive immune response' between patients with
 30 COVID-19 or influenza, a significant increase of these 83 immunoglobulin genes was detected in patients with COVID-19
 31 compared to patients with influenza.


32



33

34 **Supplementary figure 5: Significant difference in IRF7 abundance between patients with COVID-19 or influenza.** The mean
 35 abundance in patients with influenza is 1162 transcripts per million (TPM). This is significantly lower in patients with COVID-
 36 19 at 861 TPM (p -value $7.60 \cdot 10^{-03}$). Statistical testing done with Wilcoxon test.

37




Cluster 1

COVID-19 survivors
 GO biological process term
 'humoral immune response mediated by circulating immunoglobulin'
 (FDR p-value $2.23 \cdot 10^{-46}$)

Cluster 2

COVID-19 survivors
 GO biological process term
 'nucleosome assembly'
 (FDR p-value $5.46 \cdot 10^{-19}$)



Cluster 3 (brown)

COVID-19 non-survivors
 GO biological process term
 'regulation of T-helper 1 cytokine production'
 (FDR p-value $4.24 \cdot 10^{-03}$)



Cluster 4 (magenta purple)

COVID-19 survivors
 GO biological process term
 'regulation of T cell activation'
 (FDR p-value $4.51 \cdot 10^{-04}$)

38

39 **Supplementary figure 6: Top 4 clusters identified between COVID-19 survivors and non-survivors.** For each cluster the
 40 predicted Gene Ontology (GO) biological process term identified by ToppGene are given, together with enrichment found in
 41 either COVID-19 survivors or non-survivors. From these top 4 clusters combinations of 100 genes were selected as potential
 42 predictor variables of COVID-19 outcome using Boosted Logistic Regression, Bayesian Generalised Linear and RandomForest
 43 models.

44